Search

Management of Immune Related Adverse Events

Alicia Rigby, AOCNP

Immunotherapy for Kidney and Bladder Malignancies

Pedro Barata, MD, MSc

Toxicities in Immunotherapy

Lisa Kottschade, APRN

Adjuvant/Neo-Adjuvant Systemic Therapy

Heather Wakelee, MD

Novel Frontiers in the Use of ctDNA in...

Christian Rolfo, MD, PhD, MBA, Dr.hc

Management of Immune Related Adverse Events

Alicia Rigby, RN, MSN, FNP, AOCNP

Immunotherapy in Cancer: Next Generation Biomarkers

Peter P. Lee, MD

Statistical Considerations in Early Phase Clinical Trial Design...

Mark Krailo, PhD

Progress in CAR-T Cell Therapies

Stephen J. Forman, MD

Immunotherapy in Lung

Luis E. Raez, MD, FACP, FCCP

Management of Common Toxicities Encountered With Checkpoint Inhibitors

Rosanna Rodriguez, PA-C

Adjuvant/Neo-adjuvant Systemic Therapy

Heather Wakelee, MD

Developmental Therapeutics and Novel Agents

Ignacio Gil-Bazo, MD

Chimeric Antigen Receptor T-cell therapy in 2020: Current...

Mohamed A. Kharfan-Dabaja, MD, MBA, FACP

Common Misunderstandings in IO

Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Immunotherapy and Targeted Therapy in Melanoma

Sanjiv S. Agarwala, MD

Immunotherapy in Kidney & Bladder Cancers

David I. Quinn, MBBS, PhD, FRACP, FACP

Immunotherapy in Lung Cancer

Hossein Borghaei, DO, MS

Radiotherapy & Immunotherapy Applications in Oncology

Puneeth Iyengar, MD, PhD

Targeted Therapies in Cancer: Is Targeting the Same...

Shivaani Kummar (OHSU)